SEC Form 4 · accession 0001209191-16-150909
MARRONE BIO INNOVATIONS INC · MBII
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
James Boyd
Officer — Chief Financial Officer
Period of report
Nov 16, 2016
Accepted (ET)
Nov 17, 2016 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001441693
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.34 | Nov 16, 2016 | A | 200,000 | A | — | Apr 16, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the Vesting Commencement Date of October 16, 2016, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, subject to Optionee's continued employment.